eGenesis Announces World's First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient [Yahoo! Finance]
Eledon Pharmaceuticals, Inc. (ELDN)
Company Research
Source: Yahoo! Finance
Transplant was conducted at Massachusetts General Hospital and authorized by the U.S. FDA under a single Expanded Access protocol CAMBRIDGE, Mass., March 21, 2024 BUSINESS WIRE eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway and performed by a surgical team at Massachusetts General Hospital (MGH) led by Tatsuo Kawai, MD, PhD and Nahel Elias, MD. The patient suffers from end-stage renal disease and lacked other therapeutic options following the loss of vascular access to support continued use of dialysis. Following the procedure, the patient is in good condition and recovering well at MGH. More than 800,000 people in the U.S., and millions globally, suffer from end-stage renal diseas
Show less
Read more
Impact Snapshot
Event Time:
ELDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELDN alerts
High impacting Eledon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ELDN
News
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsGlobeNewswire
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionGlobeNewswire
- Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.MarketBeat
ELDN
Earnings
- 11/9/23 - Beat
ELDN
Analyst Actions
- 3/22/24 - HC Wainwright
ELDN
Sec Filings
- 4/26/24 - Form 10-K/A
- 3/28/24 - Form 10-K
- 3/28/24 - Form 8-K
- ELDN's page on the SEC website